(VELA) Study of BLU-222 in Advanced Solid Tumors
Trial ID or NCT#
NCT05252416
Status
NOT RECRUITING
Purpose
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
Official Title
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Shreya Perepa
View on